Response Genetics, Inc. Reports Third Quarter 2009 Financial Results Driven by 100 Percent Increase in ResponseDX(TM) Revenues

LOS ANGELES--(BUSINESS WIRE)--Response Genetics Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests for cancer, today announced its consolidated financial results for the three and nine months ended September 30, 2009.